Metformin and Myoinositol for Polycystic Ovary Syndrome: A Review of their Combined Effectiveness

Authors: Dr. Kaberi Banerjee, Dr. Ameet Patki, Dr. Basab Mukherjee, Sushrut Oza

DOI: 10.18231/j.ijogr.8998.1309894090

Keywords: PCOS, Insulin Resistance, Metformin,Myoinositol,Poly Cystic Ovary Syndrome

Abstract: Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine heterogeneous disorder. The complex etiology of PCOS involves hormonal imbalances, genetics, lifestyle, and environmental factors. Insulin resistance is one of the most significant pathophysiological traits in both obese and lean females with PCOS. Both obese and lean women with PCOS are vulnerable to the problem of insulin resistance. The Indian phenotype has been shown to have a predominance of PCOS associated with insulin resistance. Insulin sensitizers improve insulin sensitivity, thereby lowering insulin levels and managing the hormonal and metabolic abnormalities associated with PCOS. Insulin sensitizers like metformin, inositols, and chromium are commonly used in the treatment of PCOS. Metformin and Myoinositol in combination have been found to be synergistically beneficial for alleviating the symptoms of PCOS by enhancing insulin sensitivity at the different targets in the cascade of insulin resistance. Recent data from clinical trials and meta-analysis has highlighted the potential benefits of combining metformin and myoinositol in managing PCOS symptoms such as menstrual irregularity, hyperandrogenism, insulin resistance, and infertility. The aim of this review is to summarize currently available data on the metformin and myoinositol combination therapy in PCOS patients.